A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

December 24, 2020

Study Completion Date

February 11, 2021

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

efgartigimod IV

intravenous infusions of efgartigimod

BIOLOGICAL

efgartigimod PH20 SC

subcutaneous injections of efgartigimod PH20 SC

Trial Locations (1)

Study Site 1, Groningen